Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In high-risk patients, CGH+SNP microarray analysis of primary neuroblastoma identifies SRCIN1 as frequently altered by hemizygous deletion, copy-neutral loss of heterozygosity, or disruption.
|
31285546 |
2020 |
Central neuroblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We here used whole-exome sequencing, mRNA expression profiling, array CGH and DNA methylation analysis to characterize 16 paired samples at diagnosis and relapse from individuals with neuroblastoma.
|
26121086 |
2015 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma.
|
24737690 |
2014 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genome-wide microarray expression and genomic alterations by array-CGH analysis in neuroblastoma stem-like cells.
|
25392930 |
2014 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A subset of NBs treated at Institut Curie and harbouring MNA as determined by array-CGH without other amplification was also studied.
|
25013904 |
2014 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genomic amplification of the MYCN oncogene has been used to predict outcome in neuroblastoma for over 30 years, however, recent methodological advances including miRNA and mRNA profiling, comparative genomic hybridization (array-CGH), and whole-genome sequencing have enabled the detailed analysis of the neuroblastoma genome, leading to the identification of new prognostic markers and better patient stratification.
|
23274701 |
2013 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A focal 5 kb gain encompassing the MYCN regulated miR-17~92 cluster as sole gene was detected in a neuroblastoma cell line and further analyses of the array CGH data set demonstrated enrichment for other MYCN target genes in focal gains and amplifications.
|
23308108 |
2013 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We analyzed DNA profiling data (CGH and SNP arrays) and mRNA expression data of 31 genes of the intrinsic apoptotic pathway in a dataset of 88 neuroblastoma tumors using the R2 bioinformatic platform ( http://r2.amc.nl).
|
22788920 |
2012 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate the role of patients' age in tumor aggressiveness, we performed array-CGH and gene expression profiles of three groups (G) of metastatic NBs: G1, stage 4S patients and MYCN single copy (MYCN-) tumors; G2, stage 4 patients, ≤ 18 months of age, MYCN- tumors and favorable outcome and G3, Stage 4 patients, ≥ 19 months with unfavorable outcome.
|
22234802 |
2012 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison with array CGH and the established Multiplex Ligation-dependent Probe Amplification method on 52 neuroblastoma tumors showed that Multiplex Amplicon Quantification can reliably detect the important genomic aberrations.
|
20459859 |
2010 |
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have analyzed a set of neuroblastoma (n = 145) that is broadly representative of the genetic subtypes of this disease for miRNA expression (430 loci by stem-loop RT qPCR) and for DNA copy number alterations (array CGH) to assess miRNA involvement in disease pathogenesis.
|
19924232 |
2009 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High resolution oligonucleotide array CGH analysis of NBL has previously identified microdeletions that are confined to the 5' UTR of the protein tyrosine phosphatase receptor D (PTPRD) gene, implicating this gene in the pathogenesis of these tumors.
|
18050303 |
2008 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
High-resolution oligonucleotide array CGH mapping of chromosome 3p breakpoints relative to the positions of known TSGs indicates that more than one gene may contribute to neuroblastoma pathogenesis.
|
17452250 |
2007 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we summarize recent array CGH findings in neuroblastoma, a pediatric tumor of the sympathetic nervous system.
|
17124410 |
2006 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, the (1;4) fusion was present at diagnosis and at relapse, whereas the (4;17) fusion was detected at relapse only, leading to a secondary 17q gain confirmed by array CGH therefore indicating that 17q gain may not be a primary event in neuroblastoma.
|
15735707 |
2005 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH.
|
16075461 |
2005 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Three parental neuroblastoma cell lines and nine derived lines resistant to Vincristin, Doxorubicin and Cisplatin, respectively, using CGH were studied.
|
16151587 |
2005 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
|
15380028 |
2004 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors.
|
14500357 |
2003 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that a combination of M-FISH with banding analysis, standard FISH, and CGH allowed a detailed description of the genetic alterations in 16 neuroblastoma cell lines.
|
11550280 |
2001 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status.
|
11044353 |
2000 |